01
Cash & equivalents decreased 61.7%
Cash & equivalents changed -61.7% from the comparable as-filed period.
$13.1M→$5.0MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTTraws Pharma, Inc.'s latest supported as-filed period reports revenue of $2.8M, 4694.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -61.7% from the comparable as-filed period.
Net income changed -233.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating income changed -154.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TRAW · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-097261SEC ↗8-KAug 14, 2026Period Aug 14, 20260001104659-26-097226SEC ↗8-KJul 31, 2026Period Jul 29, 20260001104659-26-089220SEC ↗4Jul 16, 2026Period Jul 9, 20260002018150-26-000003SEC ↗4Jul 15, 2026Period Jul 9, 20260001237419-26-000003SEC ↗4Jul 15, 2026Period Jul 9, 20260002017800-26-000003SEC ↗4Jul 14, 2026Period Jul 9, 20260001203603-26-000003SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 9, 2026Filed Jul 16, 2026 | Pauza Charles DavidChief Science Officer Virology | Grant Or AwardDirect | 97,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Revenue changed +4694.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +677.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001681955-26-000002